Non-invasive serum biomarkers such as soluble PD-L1 (233) cytokines (234) and peripheral mononuclear cells (235) have been described in monitoring response to immune therapy in non-CNS tumors (236) but similar studies have not been performed extensively in glioblastoma. This evidence concerns the gene CD274 and central nervous system neoplasm.